Changchun High-Tech Industry (000661.SZ): The domestic production drug registration clinical trial application for Fuxinqibai Monoclonal Antibody Injection has been accepted.
Changchun High-Tech Industry (000661.SZ) announced that its subsidiary, Changchun GeneScience Pharmaceutical Co., Ltd. (hereinafter referred to as "GeneScience Pharmaceuticals"), has received the "Notice of Acceptance" from the National Medical Products Administration. The domestic production drug registration clinical trial application for GeneScience Pharmaceuticals' Fuxinqibai Monoclonal Antibody Injection has been accepted. Fuxinqibai Monoclonal Antibody is a fully human anti-interleukin-1 (IL-1) monoclonal antibody developed by GeneScience Pharmaceuticals, intended for the treatment of connective tissue disease-associated interstitial lung disease (CTD-ILD).
Changchun High-Tech Industry (000661.SZ) announced that its subsidiary, Changchun GeneScience Pharmaceutical Co., Ltd. (hereinafter referred to as "GeneScience Pharmaceuticals"), has received a Notice of Acceptance from the National Medical Products Administration. The domestic production drug registration clinical trial application for GeneScience Pharmaceuticals' Fuxinqibai Monoclonal Antibody Injection has been accepted. Fuxinqibai Monoclonal Antibody is a fully human anti-interleukin-1 (IL-1) monoclonal antibody developed by GeneScience Pharmaceuticals, intended for the treatment of connective tissue disease-associated interstitial lung disease (CTD-ILD).
Related Articles
INTELLIMARK AI (08041) Announces Annual Results: Loss Attributable to Shareholders Widens 477.47% Year-on-Year to HK$51.435 Million
5100 XIZANG (01115) completes issuance of 380 million consideration shares.
A-Share Announcement Highlights | Over 1.3 billion yuan! CPO leader Zhongji Innolight to distribute first-half dividends.
INTELLIMARK AI (08041) Announces Annual Results: Loss Attributable to Shareholders Widens 477.47% Year-on-Year to HK$51.435 Million
5100 XIZANG (01115) completes issuance of 380 million consideration shares.
A-Share Announcement Highlights | Over 1.3 billion yuan! CPO leader Zhongji Innolight to distribute first-half dividends.
